ArticleFrontiers in immunology2023

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.

Yujing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.